Osman, Afaf E. G.
Luke, Jason J.
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-17-1-0265)
Article History
First Online: 2 January 2019
Compliance with Ethical Standards
:
: Jason J. Luke has received the following funding: Department of Defense Career Development Award (W81XWH-17-1-0265), the Arthur J Schreiner Family Melanoma Research Fund, the J. Edward Mahoney Foundation Research Fund, Brush Family Immunotherapy Research Fund, and Buffet Fund for Cancer Immunotherapy.
: Jason J. Luke declares the following: <i>consultancy</i>—7 Hills, Aduro, Actym, Alphamab Oncology, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, Compugen, EMD Serono, Gilead, Ideaya, Janssen, Merck, NewLink, Novartis, RefleXion, Spring Bank, Syndax, Tempest, and WntRx; <i>research support</i> (all institutional except as marked)—AbbVie, Array (personal), Boston Biomedical, Bristol-Myers Squibb, Celldex, CheckMate (personal), Corvus, Delcath, Evelo (personal), Five Prime, Genentech, Immunocore, Incyte, MedImmune, Macrogenics, Novartis, Pharmacyclics, Palleon (personal), Merck, Tesaro, and Xencor; <i>travel</i>—Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Ideaya, Janssen, Merck, NewLink, Novartis, and RefleXion. <i>Patents</i>: Jason J. Luke is a co-inventor on a patent submitted by the University of Chicago covering use of microbiota to improve cancer immunotherapy outcomes. Afaf E.G. Osman declares that she has no conflicts of interest that might be relevant to the contents of this manuscript.